Two competing industry visionaries join forces to tackle telecom’s biggest challenge

 

Despite the astounding advances in technology the last 30 years, geospatial data and quality in telecommunications has not improved. Why is this? Tom Counts, president and CEO of 3-GIS, and Peter Batty, chief research officer of SSP Innovations, sat down with Host Daniel Litwin to dive into this phenomenon.

This data is essential because it provides a base of truth to dictate decision making. “The GIS set data is the center of the truth. If you don’t know the truth, you’re in trouble. If you want to run a business and you don’t understand your assets, you don’t understand that they’re accurate. It’s hard for you to assign them; it’s impossible for you to provision them; it’s troublesome for you to try to repair them,” Counts stated.

The quicker one can get from the edge to the database, the less likely there is for corruption. People tend to want to go through cycles of review of data, which can corrupt its accuracy. So those extracting data from the edge need to be trained to inspect, recognize and post data in the field and trust for it to come in while only looking for irregularities. 95% of the time it will be accurate and correct. “Having high quality geospatial data is fundamental to being able to quickly diagnose where the problem is and fix it,” Batty said.

Currently, the number of tools available today, such as augmented reality (AR), machine learning and full automation, help improve data quality. For instance, gaming, such as Pokémon Go, is helping to create a map of the world, and home design and AR are also playing a role in improving data quality.

For more information on the geospatial data in the telecommunications sector, visit www.3-GIS.com or subscribe to the Fiberside Chat podcast on Apple iTunes or Spotify.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More